Skip to main content

Menu

BNF for Children May 2025 Update

This update contains 5 significant changes, 1 dose change, 2 new monographs, 3 new preparations, and 1 deleted preparation.

Significant Changes:

  • Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice.
  • Asthma, chronic: updated guidance on management.
  • Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms): new indication and dose for mild asthma, reliever therapy.
  • Budesonide with formoterol (Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy.
  • Prolonged-release opioids: removal of indication for relief of post-operative pain [MHRA/CHM advice] (advice in all opioids; see example in oxycodone hydrochloride).

 

Dose Changes:

  • Rosuvastatin [update to dose adjustments due to interactions].

 

New Monographs:

  • Ospolot® [sultiame].
  • Winlevi® [clascoterone].

 

New Preparations: Fobumix® 80/4.5 Easyhaler [budesonide with formoterol]; Fobumix® 160/4.5 Easyhaler [budesonide with formoterol]; Fobumix® 320/9 Easyhaler [budesonide with formoterol].

 

Deleted Preparations: Ambisome® [amphotericin B].